Search

AF solution

Chevron

Regulatory T cell

Regulatory T cells (Treg)” play a crucial role in maintaining immune homeostasis and tolerance by suppressing immune responses.
These lymphocytes inhibit T cell proliferation and cytokine production, thus preventing autoimmune reactions.
Our method involves evaluating the efficacy of an anticancer agent by treating a mixture of tumor organoids, cytotoxic T cells (CD8+ T cells), and regulatory T cells (Tregs) with the anticancer drug or drug candidate.

Starting cost
€ 0 +

Cytotoxic T cell

Colorectal cancer organoids accurately replicate the complexities of patient tumors, including heterogeneity,
genetic traits, and tissue structure.
These organoids serve as a versatile platform for drug testing, allowing the evaluation of drug responses and sensitivity.
Additionally, they facilitate personalized disease modeling using patient-specific samples, contributing to biomarker identification for prognosis and treatment response.

NSCLC organoids, reflecting the heterogeneity and genetic features of patient tumors, provide a versatile platform for in-depth cancer research.
These organoids faithfully mimic the tissue architecture of NSCLC, facilitating the study of tumor dynamics, invasion patterns, and drug responses.
Their patient-specific modeling capability allows personalized exploration of treatment outcomes.

Experiment

Regulatory T cell

A drug evaluation solution co-culturing Treg, T cells, and cancer organoids allows for the assessment of drugs that can regulate Treg.
This provides a drug evaluation solution capable of evaluating drugs that can modulate Treg.

Process

Connect with Us

By submitting your details, you confirm that you have reviewed and agree with the Lambda Biologics Privacy Policy.